17 β -Estradiol Confers Protection after Traumatic Brain Injury in the Rat and Involves Activation of G Protein-Coupled Estrogen Receptor 1
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Abstract Traumatic brain injury (TBI) is a significant public health problem in the United States. Despite preclinical success of various drugs, to date all clinical trials investigating potential therapeutics have failed. Recently, sex steroid hormones have sparked interest as possible neuroprotective agents after traumatic injury. One of these is 17β-estradiol (E2), the most abundant and potent endogenous vertebrate estrogen. The goal of our study was to investigate the acute potential protective effects of E2 or the specific G protein-coupled estrogen receptor 1 (GPER) agonist G-1 when administered in an intravenous bolus dose 1 hour post-injury in the lateral fluid percussion (LFP) rodent model of TBI. The results of this study show that, when assessed at 24 hours post-injury, E2 or G-1 confers protection in adult male rats subjected to LFP brain injury. Specifically, we found that an acute bolus dose of E2 or G-1 administered intravenously 1 hour post-TBI significantly increases neuronal survival in the ipsilateral CA 2/3 region of the hippocampus and decreases neuronal degeneration and apoptotic cell death in both the ipsilateral cortex and CA 2/3 region of the hippocampus. We also report a significant reduction in astrogliosis in the ipsilateral cortex, hilus, and CA 2/3 region of the hippocampus. Finally, these effects were observed to be chiefly dose-dependent for E2, with the 5 mg/kg dose generating a more robust level of protection. Our findings further elucidate estrogenic compounds as a clinically relevant pharmacotherapeutic strategy for treatment of secondary injury following TBI, and intriguingly, reveal a novel potential therapeutic target in GPER.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
National Center for Injury Prevention and Control (U.S.). Division of Injury Response., Faul, M., Wald, M. M., Wu, L., & Coronado, V. G. (2010) · doi:10.15620/cdc.5571 · Cited by 3,494
Pathophysiology of traumatic brain injury
Werner, C., & Engelhard, K. (2007) · British Journal of Anaesthesia · doi:10.1093/bja/aem131 · Cited by 1,712
Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration
Schmued, L. C., & Hopkins, K. J. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02513-0 · Cited by 1,218 · cited 1×
“Fluoro-Jade B is an anionic fluorescein derivative that binds to degenerating neurons.(38) 1532 DAY ET AL.”
The G-protein-coupled estrogen receptor GPER in health and disease
Prossnitz, E. R., & Barton, M. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.122 · Cited by 925 · cited 4×
“Thus, our findings further elucidate estrogenic compounds as a clinically relevant pharmacotherapeutic strategy for treatment of secondary injury following TBI, and intriguingly, reveal a novel potential therapeutic target in GPER.”
InfluentialEng, L. F., & Ghirnikar, R. S. (1994) · Brain Pathology · doi:10.1111/j.1750-3639.1994.tb00838.x · Cited by 864
Loane, D. J., & Faden, A. I. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.09.005 · Cited by 574 · cited 1×
“Despite preclinical successes, to date all clinical trials investigating potential therapeutics have failed.(1) In addition, the financial burden associated with TBI is estimated at roughly $60 billion a year.”
Extranuclear Steroid Receptors: Nature and Actions
Hammes, S. R., & Levin, E. R. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0022 · Cited by 475 · cited 3×
“Thus, our findings further elucidate estrogenic compounds as a clinically relevant pharmacotherapeutic strategy for treatment of secondary injury following TBI, and intriguingly, reveal a novel potential therapeutic target in GPER.”
Bramlett, H. M., & Dietrich, W. D. (2001) · Journal of Neurotrauma · doi:10.1089/089771501750451811 · Cited by 213
Bao, Y.-J., Li, L.-Z., Li, X.-G., & Wang, Y.-J. (2011) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2011.07.004 · Cited by 30
Cited by
Cooke, P. S., Nanjappa, M. K., Ko, C., Prins, G. S., & Hess, R. A. (2017) · Physiological Reviews · doi:10.1152/physrev.00018.2016 · Cited by 466
Sex-related responses after traumatic brain injury: Considerations for preclinical modeling
Späni, C. B., Braun, D. J., & Van Eldik, L. J. (2018) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2018.03.006 · Cited by 195
Rahman, A., Jackson, H., Hristov, H., Isaacson, R. S., Saif, N., Shetty, T., Etingin, O., Henchcliffe, C., Brinton, R. D., & Mosconi, L. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00315 · Cited by 187
“Estrogen administration pre- and postTBI is associated with increased neuronal survival, significant reductions in apoptosis, and improvements in functional outcomes (Soustiel et al., 2005; Day et al., 2013; Naderi et al., 2015).”
BackgroundAzcoitia, I., Barreto, G. E., & Garcia-Segura, L. M. (2019) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2019.100787 · Cited by 125
Sex differences in orbitofrontal connectivity in male and female veterans with TBI
McGlade, E., Rogowska, J., & Yurgelun-Todd, D. (2015) · Brain Imaging and Behavior · doi:10.1007/s11682-015-9379-3 · Cited by 63
The role of G protein-coupled estrogen receptor 1 on neurological disorders
Roque, C., Mendes-Oliveira, J., Duarte-Chendo, C., & Baltazar, G. (2019) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2019.100786 · Cited by 41
Colón, J. M., González, P. A., Cajigas, Á., Maldonado, W. I., Torrado, A. I., Santiago, J. M., Salgado, I. K., & Miranda, J. D. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2017.10.006 · Cited by 19
Metadata
- Authors
- Day, N. L., Floyd, C. L., D'Alessandro, T. L., Hubbard, W. J., & Chaudry, I. H.
- Venue
- Journal of Neurotrauma
- Publisher
- SAGE Publications
- Published
- 2013-09
- Volume
- 30
- Issue
- 17
- Pages
- 1531-1541
- ISSN
- 0897-7151 (ISSN-L)
- 1557-9042
- OpenAlex
- W2134186952
- Cited by
- 90
- References
- 9
- FWCI
- 4.75
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.